Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1995-04-28
1999-11-02
Elliott, George C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
4242101, 435 693, 4353201, A61K 39145, C12N 1563
Patent
active
059765526
ABSTRACT:
Improved mammalian virus vaccines are combinations that contain an immunogenic amount of inactivated virus, such as influenza virus, Herpes varicella virus, measles virus, Epstein Barr virus, respiratory syncytial virus, parainfluenza 3, Herpes simplex type 1 virus, and Herpes simplex type 2 virus, and an immunogenic amount of a purified recombinant envelope protein from the virus, or a fragment or precursor of the protein. Alternatively, they contain either inactivated virus and/or envelope protein antigens and an adjuvant such as granulocyte-microphage colony stimulating factor. One embodiment of an influenza vaccine is prepared by combining inactivated virus, preferably three strains of the virus, and hemagglutinin, preferably a combination of respective hemagglutinins for each of the three strains present. In another embodiment, an influenza vaccine is prepared by combining inactivated virus, again preferably three strains of the virus, and neuraminidase, preferably a combination of respective neuraminidase for each of the three strains present. In a third embodiment, the vaccine contains inactivated virus and both hemagglutinin and neuraminidase, preferably using three strains of each. Granulocyte-macrophage colony stimulating factor is, optionally, added to these embodiments.
REFERENCES:
Johansson et al. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virology vol. 67, pp. 5721-5723, 1993.
Johansson et al. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virology vol. 63 pp. 1239-1246, 1989.
Kuroda et al. The oligosaccharides of influenza virus hemagglutinin expressed in insect cells by a baculovirus vector. Virology vol. 174, pp. 418-429, 1990.
Kuroda et al. Retarded processing of influenza virus hemagglutinin in insect cells. Virology vol. 180 pp. 159-165, 1991.
Chazenbalk et al. Expression of the extracellular domain of the thyrotropin receptor in the baculovirus system using a promiter active earlier than the polyhedrin promoter. J. Biol. Chem. vol. 270 pp. 1542-1548, 1995.
Physicians Desk Reference, 48th Edition, Medical Economics Data Production Co. pp. 1160-1162, 1994.
Ada, G.L., and Jones, P.D., Curr. Top. Microbiol. Immunol. 128: 1-54 (1986).
Kendal, A.P., et al., J. Infect. Dis. 136: S415-24 (1977).
Murphy, B.R., et al., N. Engl. J. Med. 286:1329-1332 (1972).
Nichol., K.L., et al., Arch. Int. Med. 152: 106-110 (1992).
Rocha et al. Comparison of 10 influenza A (H1N1) and H3N2) haemagglutinin sequences obtained directly from clinical specimens t those of MDCK cell-and egg-grown viruses. J. Gen. Virology vol. 74 pp. 2513-2518, 1993.
Nerome et al. Evolutionary pathways of N2 neuraminidases of swine and human influenza A viruses: origin of the neuraminidase genes of two reassortants (H1N2) isolated from pigs. J. Gen. Virology vol. 72 pp. 693-698 (1991).
Weyer et al. A baculovirus dual expression vector derived from the Autographa californica nuclear polyhedrosis virus polyhedrin and p10 promoters: co-expression of two influenza virus genes in insect cells. J. Gen. Virology vol. 72 pp. 2967-2974, 1991.
Vanlandschoot et al. Recombianant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. Vaccine vol. 11 pp. 1185-1187, 1993.
Kilbourne Inactivated influenza vaccines. in Vaccines Plotkin and Mortimer, Eds., W.B. Saunders Co. Philadelphia pp. 420-434, 1988.
Brusca John S.
Elliott George C.
Kowalski Thomas J.
Protein Sciences Corporation
LandOfFree
Virus vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Virus vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virus vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2131599